Pharma stocks: Nomura gives 'Buy' to Lupin remains 'Neutral' on others

Lupin is preparing the launch of PredForte, having a market of $200 million with 180 days competitive generic therapy (CGT) exclusivity in the near term

The Indian pharmaceutical giants are taking a halt in filing new drug applications, with new filings lowest in the past 19 years, says a latest report by Japanese brokerage firm, Nomura. 

However, this is not concerning the report says, as the Indian pharmaceutical majors are going for quality over quantity. While the number of ANDA filings in Oct’23-Jun’24 declined to 521 versus 567 in the previous year. Filings classified as complex contributed 20 per cent and 16 per cent respectively in these periods. The industry is thus selective and targeting complex products, the brokerage report said.